{"id":"intramuscular-paraldehyde","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Drowsiness"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in a calming effect on the nervous system, reducing anxiety and seizure activity. Paraldehyde's mechanism of action is complex and not fully understood, but it is thought to involve the inhibition of GABA transaminase, leading to increased GABA levels and a subsequent decrease in neuronal excitability.","oneSentence":"Paraldehyde is a sedative and anticonvulsant that acts by inhibiting the activity of GABA transaminase, leading to increased levels of GABA in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:43.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alcohol withdrawal"},{"name":"Seizure disorders"}]},"trialDetails":[{"nctId":"NCT00116064","phase":"PHASE3","title":"Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions","status":"COMPLETED","sponsor":"Kamuzu University of Health Sciences","startDate":"2004-07","conditions":"Status Epilepticus, Convulsions","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"intramuscular paraldehyde","genericName":"intramuscular paraldehyde","companyName":"Kamuzu University of Health Sciences","companyId":"kamuzu-university-of-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intramuscular paraldehyde has been studied as a treatment for pediatric convulsions and status epilepticus. It has been compared to intranasal lorazepam in clinical trials, specifically in the treatment of pediatric convulsions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}